Characteristic | Hazard ratio | 95%CI | P-value |
---|---|---|---|
Endocrine Therapy | Â | Â | Â |
 No | 1.00 | reference | <0.0001 |
 Any | 0.60 | 0.47 – 0.77 |  |
SERM | Â | Â | Â |
 No | 1.00 | reference | 0.007 |
 Yes | 0.63 | 0.48 – 0.82 |  |
AI | Â | Â | Â |
 No | 1.00 | reference | <.0001 |
 Yes | 0.47 | 0.34 – 0.66 |  |
LHRH | Â | Â | Â |
 No | 1.00 | reference | 0.75 |
 Yes | 0.85 | 0.31 – 2.30 |  |
Fulvestrant | Â | Â | Â |
 No | 1.00 | reference | 0.0004 |
 Yes | 0.29 | 0.15 – 0.57 |  |
Chemotherapy | Â | Â | Â |
 No | 1.00 | reference | 0.06 |
 Yes | 0.76 | 0.57 – 1.02 |  |
Category | Â | Â | Â |
 A | 1.00 | reference |  |
 A+B | 0.8 | 0.60 – 1.07 | 0.13 |
HER2-Directed Therapy | Â | Â | Â |
 No | 1.00 | reference | 0.15 |
 Yes | 0.69 | 0.41 – 1.14 |  |
Bisphosphonate Therapy | Â | Â | Â |
 No | 1.00 | reference | 0.02 |
 Yes | 0.70 | 0.52 – 0.96 |  |
Pamidronic acid | Â | Â | Â |
 No | 1.00 | reference | 0.44 |
 Yes | 0.87 | 0.62 – 1.23 |  |
Zoledronic acid | Â | Â | Â |
 No | 1.00 | reference | 0.002 |
 Yes | 0.50 | 0.32 – 0.77 |  |